Postmenopausal hormone replacement therapy treatments that contain both estrogen and progesterone may slightly increase the risk of breast cancer, though studies suggest that short-term use of less than four to five years may not significantly affect risk, and breast cancer rates may go up only with prolonged use. Interestingly, estrogen-only hormone treatment, which is used for people who do not have a uterus, does not seem to affect breast cancer risk.
